269 related articles for article (PubMed ID: 9450562)
41. Targeting agents alone to cure acute promyelocytic leukemia.
Chen SJ; Chen Z
N Engl J Med; 2013 Jul; 369(2):186-7. PubMed ID: 23841735
[No Abstract] [Full Text] [Related]
42. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy-free treatment of acute promyelocytic leukemia.
Ravandi F
Clin Adv Hematol Oncol; 2015 Aug; 13(8):498-500. PubMed ID: 26351810
[No Abstract] [Full Text] [Related]
44. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.
Darwiche N; El-Sabban M; Bazzi R; Nasr R; Al-Hashimi S; Hermine O; de Thé H; Bazarbachi A
Hematol J; 2001; 2(2):127-35. PubMed ID: 11424005
[TBL] [Abstract][Full Text] [Related]
45. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Zhang X; Yang L; Qiao Z
Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
[TBL] [Abstract][Full Text] [Related]
46. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Efficace F; Mandelli F; Avvisati G; Cottone F; Ferrara F; Di Bona E; Specchia G; Breccia M; Levis A; Sica S; Finizio O; Kropp MG; Fioritoni G; Cerqui E; Vignetti M; Amadori S; Schlenk RF; Platzbecker U; Lo-Coco F
J Clin Oncol; 2014 Oct; 32(30):3406-12. PubMed ID: 25245446
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
48. Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
Ravandi F; Kantarjian H
Lancet Oncol; 2015 Oct; 16(13):1274-5. PubMed ID: 26384240
[No Abstract] [Full Text] [Related]
49. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
50. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Park JH; Tallman MS
Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
[TBL] [Abstract][Full Text] [Related]
51. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Nichol JN; Garnier N; Miller WH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014
[TBL] [Abstract][Full Text] [Related]
52. How I treat acute promyelocytic leukemia.
Tallman MS; Altman JK
Blood; 2009 Dec; 114(25):5126-35. PubMed ID: 19797519
[TBL] [Abstract][Full Text] [Related]
53. Current treatment of acute promyelocytic leukemia.
Lo Coco F; Ammatuna E; Sanz MA
Haematologica; 2007 Mar; 92(3):289-91. PubMed ID: 17339175
[No Abstract] [Full Text] [Related]
54. How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making.
Koehler M; Fischer T
J Clin Oncol; 2015 Mar; 33(9):1090-1. PubMed ID: 25691667
[No Abstract] [Full Text] [Related]
55. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Yan J; Chen X; Shao J
Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
[No Abstract] [Full Text] [Related]
56. Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
Sanz MA; Iacoboni G; Montesinos P
Curr Oncol Rep; 2013 Oct; 15(5):445-9. PubMed ID: 23990383
[TBL] [Abstract][Full Text] [Related]
57. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Tsimberidou AM; Kantarjian H; Keating MJ; Estey E
Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899
[TBL] [Abstract][Full Text] [Related]
58. All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Tallman MS
Leuk Lymphoma; 2010 May; 51(5):745-6. PubMed ID: 20423285
[No Abstract] [Full Text] [Related]
59. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
60. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
